These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9499247)

  • 1. Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate.
    Arcangeli G; Saracino B; Micheli A; D'Angelo L; Pansadoro V; Cruciani E; Marchetti P
    Am J Clin Oncol; 1998 Feb; 21(1):1-5. PubMed ID: 9499247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
    Lawton CA; Winter K; Byhardt R; Sause WT; Hanks GE; Russell AH; Rotman M; Porter A; McGowan DG; DelRowe JD; Pilepich MV
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):931-9. PubMed ID: 9276357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
    Perez CA; Michalski J; Brown KC; Lockett MA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
    Martinez A; Galalae R; Gonzalez J; Mitchell C; Gustafson G; Kovacs G
    J Urol; 2003 Dec; 170(6 Pt 1):2296-301. PubMed ID: 14634400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.
    Whittington R; Malkowicz SB; Machtay M; Van Arsdalen K; Barnes MM; Broderick GA; Wein AJ
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):673-80. PubMed ID: 9336149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
    Lawton CA; Winter K; Grignon D; Pilepich MV
    J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study.
    Granfors T; Modig H; Damber JE; Tomic R
    J Urol; 1998 Jun; 159(6):2030-4. PubMed ID: 9598512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma.
    Sumi M; Ikeda H; Tokuuye K; Kagami Y; Murayama S; Tobisu K; Kakizoe T
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):519-28. PubMed ID: 10974471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
    Sands ME; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):13-9. PubMed ID: 7527796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.